期刊
AGEING RESEARCH REVIEWS
卷 89, 期 -, 页码 -出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.arr.2023.101965
关键词
Nanomedicine; Lipid nanosystems; Parkinson 's diesae; Neurodegeneration; Therapeutics
Parkinson's disease is the second most common neurodegenerative disorder, and the delivery of therapeutic compounds is hindered by the blood-brain barrier. Lipid nanosystems have been used for the precise delivery of therapeutic compounds in anti-PD therapy. This review discusses the application and clinical significance of lipid nanosystems in delivering therapeutic compounds for anti-PD treatment.
Parkinson's disease (PD) is the second most common neurodegenerative disorder. The degeneration of dopaminergic neurons in the midbrain is primarily responsible for the onset of the disease. The major challenge faced in the treatment of PD is the blood-brain barrier (BBB), which impedes the delivery of therapeutics to targeted locations. To address this issue, lipid nanosystems have been used for the precise delivery of therapeutic compounds in anti-PD therapy. In this review, we will discuss the application and clinical significance of lipid nanosystem in delivering therapeutic compounds for anti-PD treatment. These medicinal compounds include ropinirole, apomorphine, bromocriptine, astaxanthin, resveratrol, dopamine, glyceryl monooleate, levodopa, N 3,4-bis(pivaloyloxy)-dopamine and fibroblast growth factor, which have significant potential to treat PD in the early stage. This review, in a nutshell, will pave the way for researchers to develop diagnostic and potential therapeutic approaches using nanomedicine to overcome the challenges posed by the BBB in delivering therapeutic compounds for PD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据